Jiangsu Zhongbang Pharmaceutical Co., Ltd., founded in 2001, is a wholly-owned subsidiary of China's top 500 enterprises - Red Sun Group. Zhongbang pharmaceutical is a proposed listed company specializing in R & D, production and sales of APIs, advanced pharmaceutical intermediates and pharmaceutical preparations. The company has a registered capital of 180 million yuan. It now has four wholly-owned subsidiaries with more than 700 employees, covering a total area of more than 500 mu. Zhongbang pharmaceutical mainly produces cardiovascular and cerebrovascular drugs, digestive system drugs, anticoagulant drugs and other pharmaceutical intermediates, APIs and preparations. The products sell well in domestic and foreign markets and are recognized and praised by customers. Quality is the inherent value pursuit of Chinese people. Perfect GMP management system, complete production facilities and equipment, advanced testing instruments and information system ensure excellent and reliable product quality. The company has passed the GMP on-site inspection in China, South Korea, Japan and other countries, and many API have EU CEP certificate and China GMP certificate. Innovation is becoming the engine of China's development. Up to now, the company has 22 national invention patents and 2 preparation products are under approval. It has been recognized as Jiangsu heterocyclic medicine and intermediate engineering technology research center, enterprise technology center and innovation pilot enterprise, providing satisfactory products and services for world-famous pharmaceutical enterprises. Zhongbang pharmaceutical takes social responsibility as its own responsibility, adheres to the business philosophy of "achieving capable people, loving good people and repaying noble people", and firmly remembers the mission of "never forgetting the original intention, happy employees and repaying society", so as to provide customers with high-quality products and services and contribute to the cause of human health.